Sequelae of treatment in long-term survivors of testis cancer

European Urology

Volumn 60, Issue 3, 2011, Pages 516-526

  Abouassaly, Robert ^a   Fossa, Sophie D ^b,h   Giwercman, Aleksander ^c   Kollmannsberger, Christian ^d   Motzer, Robert J ^e   Schmoll, Hans Joachim ^f   Sternberg, Cora N ^g  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

Germ cell and embryonal; Neoplasms; Testicular neoplasms

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BLEOMYCIN; C REACTIVE PROTEIN; CD40 LIGAND; CISPLATIN; CYTOKINE; ETOPOSIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; MAGNESIUM; PLATINUM; TESTOSTERONE; VINBLASTINE;

ATHEROGENESIS; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSEL INJURY; BODY MASS; BRONCHIOLITIS OBLITERANS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CANCER THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC FATIGUE SYNDROME; CONTRALATERAL TESTICULAR CANCER; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DORSAL ROOT; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FOLLOW UP; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; GONAD FUNCTION; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERTENSION; HYPOGONADISM; HYPOMAGNESEMIA; INCIDENCE; INFERIOR CAVA VEIN; INFLAMMATION; INFORMATION RETRIEVAL; INSULIN RESISTANCE; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; LEUKEMIA; LIFE EXPECTANCY; LUNG EMBOLISM; LUNG FIBROSIS; LUNG TOXICITY; MALE FERTILITY; MALE GENITAL TRACT CANCER; MEDLINE; MICROALBUMINURIA; MORBIDITY; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NERVE DEGENERATION; NEUROPATHY; NEUROTOXICITY; OBESITY; OTOTOXICITY; OXIDATIVE STRESS; PERIPHERAL NEUROPRAXIA; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; SEMINOMA; SEXUAL DYSFUNCTION; SMOKING; SOLID TUMOR; TESTIS CANCER; TESTIS NONSEMINOMA CANCER; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; INFERTILITY, MALE; KIDNEY DISEASES; MALE; NEOPLASMS; NEUROTOXICITY SYNDROMES; ORCHIECTOMY; RADIATION INJURIES; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960972513     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.05.055     Document Type: Review

References (129)

1. Verdecchia A, Francisci S, Brenner H, et al., EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784-96.
2. Aparicio J, Diaz R. Management options for stage I seminoma. Expert Rev Anticancer Ther 2010;10:1077-85.
3. Jewett MA, Kong YS, Goldberg SD, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988;139:1220-4.
4. Huddart R, Kataja V, ESMO Guidelines Working Group. Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii52-4.
5. deWit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germcell cancer: a randomized study of the European Organization forResearchand Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19:1629-40.
6. Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 2010;102:1253-62.
7. Fosså SD, Oldenburg J, Dahl AA. Short- and long-term morbidity after treatment for testicular cancer. BJU Int 2009;104:1418-22.
8. Abouassaly R, Klein EA, Raghavan D. Complications of surgery and chemotherapy for testicular cancer. Urol Oncol 2005;23:447-55. (Pubitemid 41654516)
9. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114-30.
10. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992;10:1386-9. (Pubitemid 23059920)
11. Gietema JA, Sleijfer DT, Willemse PH, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992;116:709-15. (Pubitemid 23033113)
12. Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004;40:701-6. (Pubitemid 38326620)
13. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005;23:9130-7.
14. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008;112:1949-53. (Pubitemid 351574070)
15. Wethal T, Kjekshus J, Røislien J, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007;1:8-16.
16. Fukui M. Testicular cancer and syndrome X. Lancet 2001;358:242.
17. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718-25.
18. Haugnes HS, Aass N, Fosså SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18:241-8. (Pubitemid 46323088)
19. de Haas EC, Sleijfer DT, Gietema JA. Follow-up of successfully treated testicular cancer patients: consequences of the metabolic syndrome. Ann Oncol 2007;18:211-2. (Pubitemid 46323083)
20. Hentrich M, Fegg MJ, Meiler S, Jost C, Gerl A. Smoking cessation in long-term survivors of germ cell tumour. J Cancer Res Clin Oncol 2006;132:557-60. (Pubitemid 44078524)
21. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32. (Pubitemid 30220551)
22. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649-57.
23. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981;95:288-92. (Pubitemid 11052696)
24. Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990;8: 21-6. (Pubitemid 20032442)
25. Hansen SW, Olsen N. Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol 1989;7:940-2. (Pubitemid 19172469)
26. Albers P, Melchior D, Müller SC. Surgery in metastatic testicular cancer. Eur Urol 2003;44:233-44. (Pubitemid 36917009)
27. Spitz A, Wilson TG, Kawachi MH, Ahlering TE, Skinner DG. Vena caval resection for bulky metastatic germ cell tumors: an 18-year experience. J Urol 1997;158:1813-8. (Pubitemid 27433159)
28. Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg 1998;28:808-14. (Pubitemid 28521018)
29. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274-81. (Pubitemid 8350173)
30. Fjeldborg P, Sørensen J, Helkjaer PE. The long-term effect of cisplatin on renal function. Cancer 1986;58:2214-7. (Pubitemid 17170898)
31. Hansen SW, Groth S, Daugaard G, Rossing N, Rørth M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988;6:1728-31. (Pubitemid 19089052)
32. Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981;95:628-32. (Pubitemid 12231806)
33. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90:929-31. (Pubitemid 9244593)
34. Fosså SD, Aass N, Winderen M, Börmer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002;13:222-8. (Pubitemid 34704973)
35. Pliarchopoulou K, Pectasides D. Late complications of chemotherapy in testicular cancer. Cancer Treat Rev 2010;36:262-7.
36. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
37. Bosl GJ, Leitner SP, Atlas SA, Sealey JE, Preibisz JJ, Scheiner E. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986;4:1684-9. (Pubitemid 17188938)
38. Dewit L, Anninga JK, Hoefnagel CA, Nooijen WJ. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990;19:977-83. (Pubitemid 20345169)
39. Mulla MG, Ananthkrishnan G, Mirza MS, Bungay P, Puri S, Chakraborti P. Renal artery stenosis after radiotherapy for stage I seminoma, a case report. Clin Oncol (R Coll Radiol) 2007;19:209.
40. Irwin C, Fyles A, Wong CS, Cheung CM, Zhu Y. Late renal function following whole abdominal irradiation. Radiother Oncol 1996; 38:257-61.
41. Baniel J, Foster RS,Rowland RG, Bihrle R, Donohue JP. Complications of primary retroperitoneal lymph node dissection. J Urol 1994; 152:424-7. (Pubitemid 24221235)
42. Sheinfeld J, Sogani P. Reoperative retroperitoneal surgery. Urol Clin North Am 2007;34:227-33. (Pubitemid 46678182)
43. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995;153:976-80.
44. Donohue JP, Rowland RG. Complications of retroperitoneal lymph node dissection. J Urol 1981;125:338-40. (Pubitemid 11143533)
45. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989;7:1457-61. (Pubitemid 19245115)
46. Mykletun A, Dahl AA, Haaland CF, et al. Side effects and cancerrelated stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 2005;23:3061-8. (Pubitemid 46224128)
47. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 1999;20:883-7. (Pubitemid 30091215)
48. McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 2001;85:1219-25. (Pubitemid 33052324)
49. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005;18:305-13. (Pubitemid 40431114)
50. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999;83:866-9.
51. Hansen SW. Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ 1990; 300:511-2. (Pubitemid 20085518)
52. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-32. (Pubitemid 26371450)
53. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982;66: 19-23. (Pubitemid 12254659)
54. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006;24:918-24. (Pubitemid 46638845)
55. Leibovitch I, Nash PA, Little Jr JS, Foster RS, Donohue JP. Spinal cord ischemia after post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell cancer. J Urol 1996;155: 947-51. (Pubitemid 26052686)
56. Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990;8:765-7. (Pubitemid 20148266)
57. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275-80. (Pubitemid 11063588)
58. Levi JA, Thomson D, Sandeman T. A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol 1988;6:1154-60.
59. Fossa SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007;99:533-44. (Pubitemid 47073556)
60. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120: 617-24. (Pubitemid 32881285)
61. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14:91-6. (Pubitemid 36150265)
62. Yousem SA, Lifson JD, Colby TV. Chemotherapy-induced eosinophilic pneumonia. Relation to bleomycin. Chest 1985;88:103-6.
63. Haugnes HS, Aass N, Fosså SD, et al. Pulmonary function in longterm survivors of testicular cancer. J Clin Oncol 2009;27:2779-86.
64. Mock V, Atkinson A, Barsevick A, et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 2000;14:151-61.
65. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 2002;38:27-43. (Pubitemid 34031823)
66. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000;18:743-53. (Pubitemid 30106604)
67. Knobel H, Havard Loge J, Brit Lund M, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol 2001;19:3226-33. (Pubitemid 32591440)
68. Fossa SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in longterm survivors of testicular cancer. J Clin Oncol 2003;21:1249-54. (Pubitemid 46606400)
69. Orre IJ, Fosså SD, Murison R, et al. Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 2008; 64:363-71. (Pubitemid 351417918)
70. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-11. (Pubitemid 34791163)
71. Stone P, Hardy J, Broadley K, Tookman AJ, Kurowska A, A'Hern R. Fatigue in advanced cancer: a prospective controlled crosssectional study. Br J Cancer 1999;79:1479-86. (Pubitemid 29116808)
72. Orre IJ, Murison R, Dahl AA, Ueland T, Aukrust P, Fosså SD. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun 2009;23:868-74.
73. Fossa SD, Dahl AA, Haaland CF. Health-related quality of life in patients treated for testicular cancer. Curr Opin Urol 1999;9: 425-9. (Pubitemid 30028921)
74. Rossen PB, Pedersen AF, Zachariae R, von der Maase H. Healthrelated quality of life in long-term survivors of testicular cancer. J Clin Oncol 2009;27:5993-9.
75. Joly F, Héron JF, Kalusinski L, et al. Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol 2002;20:73-80. (Pubitemid 34032598)
76. Shinn EH, Swartz RJ, Thornton BB, Spiess PE, Pisters LL, Basen- Engquist KM. Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. J Clin Oncol 2010;28:2274-9.
77. Schagen SB, Boogerd W, Muller MJ, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008;47:63-70.
78. Pedersen AD, Rossen P,Mehlsen MY, Pedersen CG, Zachariae R, von derMaase H.Long-termcognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 2009; 15:296-301.
79. Dahl AA, Haaland CF, Mykletun A, et al. Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol 2005;23:2389-95. (Pubitemid 46218733)
80. Fleer J, Sleijfer D, Hoekstra H, Tuinman M, Klip E, Hoekstra- Weebers J. Objective and subjective predictors of cancer-related stress symptoms in testicular cancer survivors. Patient Educ Couns 2006;64:142-50. (Pubitemid 44772953)
81. Shinn EH, Basen-Engquist K, Thornton B, Spiess PE, Pisters L. Health behaviors and depressive symptoms in testicular cancer survivors. Urology 2007;69:748-53. (Pubitemid 46574916)
82. de Boer AG, Taskila T, Ojajarvi A, van Dijk FJ, Verbeek JH. Cancer survivors and unemployment: a meta-analysis and metaregression. JAMA 2009;301:753-62.
83. Berg Gudbergsson S, Fossa SD, Dahl AA. Is cancer survivorship associated with reduced work engagement? A NOCWO study. J Cancer Surviv 2008;2:159-68.
84. Fleer J, Hoekstra HJ, Sleijfer DT, Tuinman MA, Klip EC, Hoekstra- Weebers JE. Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events. Support Care Cancer 2006;14:251-9. (Pubitemid 43247929)
85. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65. (Pubitemid 41487803)
86. Richiardi L, Scelo G, Boffetta P, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007;120:623-31. (Pubitemid 44969034)
87. Robinson D, Moller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 2007; 96:529-33. (Pubitemid 46215229)
88. Schairer C, Hisada M, Chen BE, et al. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 2007;99:1248-56. (Pubitemid 47299903)
89. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998;124:207-14. (Pubitemid 28216233)
90. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer 1991;68:600-4.
91. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991;78: 1147-8.
92. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
93. Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer 2002;95:1228-33.
94. Holzbeierlein JM, Sogani PC, Sheinfeld J. Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol 2003;169:2122-5.
95. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J Clin Oncol 1993;11:415-24. (Pubitemid 23071036)
96. Osterlind A, Berthelsen JG, Abildgaard N, et al. Risk of bilateral testicular germ cell cancer in Denmark: 1960-1984. J Natl Cancer Inst 1991;83:1391-5.
97. Wanderas EH, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur J Cancer 1997;33:244-52.
98. Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005;97:1056-66. (Pubitemid 41417922)
99. Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fosså SD. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7102 Norwegian patients (1953-2007). Int J Cancer. In press. DOI:10.1002/ijc.25943.
100. Oliver SE, May MT, Gunnell D. International trends in prostatecancer mortality in the "PSA ERA.". Int J Cancer 2001;92:893-8.
101. Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 1999;17:941-7. (Pubitemid 29109327)
102. Willemse PH, Sleijfer DT, Sluiter WJ, Schraffordt Koops H, Doorenbos H. Altered Leydig cell function in patients with testicular cancer: evidence for bilateral testicular defect. Acta Endocrinol (Copenh) 1983;102:616-24. (Pubitemid 13160952)
103. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93:200-7. (Pubitemid 41133206)
104. Brennemann W, Stoffel-Wagner B, Helmers A, Mezger J, Jager N, Klingmuller D. Gonadal function of patients treated with cisplatin based chemotherapy for germcell cancer. J Urol 1997;158:844-50.
105. Wiechno P, Demkow T, Kubiak K, Sadowska M, Kamińska J. The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. Eur Urol 2007;52:1448-55. (Pubitemid 47454670)
106. Nord C, Bjøro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol 2003;44:322-8. (Pubitemid 37051700)
107. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 2009;5:113-21.
108. Brown JE, Ellis SP, Silcocks P, et al. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res 2006;12:6480-6. (Pubitemid 44799721)
109. Ondrusova M, Ondrus D, Dusek L, Spanikova B. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma 2009;56:473-9.
110. Lackner JE, Koller A, Schatzl G, Marberger M, Kratzik C. Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy. Urology 2009;74:825-9.
111. Spermon JR, Kiemeney LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumors. Fertil Steril 2003;79(Suppl 3):1543-9. (Pubitemid 36687931)
112. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol 2005;174:1819-22. (Pubitemid 41546950)
113. Gospodarowicz M. Testicular cancer patients: considerations in long-term follow-up. Hematol Oncol Clin North Am 2008;22: 245-55. (Pubitemid 351452096)
114. Bang AK, Petersen JH, Petersen PM, Andersson AM, Daugaard G, Jørgensen N. Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys 2009;75:672-6.
115. Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004;100:732-7. (Pubitemid 38176850)
116. Brydoy M, Fossa SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005;97:1580-8. (Pubitemid 41662712)
117. Brydøy M, Fosså SD, Klepp O, et al. Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol 2010;58: 134-41.
118. Magelssen H, Melve KK, Skjaerven R, Fossa SD. Parenthood probability and pregnancy outcome in patients with a cancer diagnosis during adolescence and young adulthood. Hum Reprod 2008;23: 178-86. (Pubitemid 351767332)
119. Stahl O, Boyd HA, Giwercman A, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst 2011; 103:398-406.
120. Aass N, Grunfeld B, Kaalhus O, Fossa SD. Pre- and post-treatment sexual life in testicular cancer patients: a descriptive investigation. Br J Cancer 1993;67:1113-7. (Pubitemid 23147513)
121. Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol 1997;15: 1444-8. (Pubitemid 27167378)
122. Jonker-Pool G, van Basten JP, Hoekstra HJ, et al. Sexual functioning after treatment for testicular cancer: comparison of treatment modalities. Cancer 1997;80:454-64. (Pubitemid 27323415)
123. Caffo O, Amichetti M. Evaluation of sexual life after orchidectomy followed by radiotherapy for early-stage seminoma of the testis. BJU Int 1999;83:462-8. (Pubitemid 29151174)
124. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999;80: 801-7. (Pubitemid 29209843)
125. Stoter G, Koopman A, Vendrik CP, et al. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. J Clin Oncol 1989;7:1099-104. (Pubitemid 19196534)
126. Tinkler SD, Howard GC, Kerr GR. Sexual morbidity following radiotherapy for germ cell tumours of the testis. Radiother Oncol 1992;25:207-12.
127. Eberhard J, Stahl O, Cohn-Cedermark G, et al. Sexual function in men treated for testicular cancer. J Sex Med 2009;6:1979-89.
128. Dahl AA, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol 2007;52:1438-47.
129. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39. (Pubitemid 27419206)